Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q8BLG0

Entry ID Method Resolution Chain Position Source
AF-Q8BLG0-F1 Predicted AlphaFoldDB

61 variants for Q8BLG0

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3388596642 57 W>R No EVA
rs3392136458 90 N>D No EVA
rs3392419685 92 Q>ASTCWFI* No EVA
rs3392419685 93 V>E No EVA
rs3392471473 93 V>E No EVA
rs3392503671 95 A>T No EVA
rs3388596697 117 T>I No EVA
rs3388604594 173 T>M No EVA
rs586039672 179 D>E No EVA
rs1134791568 190 R>Q No EVA
rs1132558190 205 K>N No EVA
rs1133060557 228 E>K No EVA
rs242923733 247 K>R No EVA
rs13476860 248 N>S No EVA
rs3388600041 255 E>K No EVA
rs1134731583 263 P>L No EVA
rs3392368336 268 P>S No EVA
rs3388600049 298 L>I No EVA
rs3388590479 304 D>H No EVA
rs3388607197 318 N>Y No EVA
rs3388604721 333 T>A No EVA
rs239476987 344 S>L No EVA
rs3388605515 361 K>R No EVA
rs228544768 384 S>C No EVA
rs252205561 388 C>G No EVA
rs585641157 389 H>P No EVA
rs581889813 399 D>A No EVA
rs3388602571 446 V>M No EVA
rs3412824812 474 Y>F No EVA
rs3388597316 535 K>N No EVA
rs3388606985 565 S>R No EVA
rs3388607491 593 S>R No EVA
rs3392338532 600 D>N No EVA
rs218151613 652 D>N No EVA
rs3392430924 676 Q>P No EVA
rs3392280619 678 W>C No EVA
rs3392338537 681 G>W No EVA
rs3392457551 682 V>D No EVA
rs3392280623 682 V>L No EVA
rs3388607477 691 V>M No EVA
rs3388597282 708 P>H No EVA
rs3388590525 708 P>S No EVA
rs263010890 731 D>E No EVA
rs3388608311 737 Q>K No EVA
rs3392338451 739 A>TIFLAFWWE* No EVA
rs3388597257 751 D>G No EVA
rs3388606742 763 Q>H No EVA
rs3388606175 787 H>R No EVA
rs3388590547 790 E>K No EVA
rs1133272615 794 H>Y No EVA
rs583748471 803 A>T No EVA
rs237772575 817 A>T No EVA
rs3392503632 818 V>M No EVA
rs3392448631 822 S>P No EVA
rs3388598191 824 L>P No EVA
rs3388607241 826 R>L No EVA
rs3388604667 828 V>A No EVA
rs3388602117 836 E>G No EVA
rs3388598151 903 V>G No EVA
rs3392368335 950 E>V* No EVA
rs3388606681 989 H>R No EVA

No associated diseases with Q8BLG0

7 regional properties for Q8BLG0

Type Name Position InterPro Accession
domain Zinc finger, PHD-type 657 - 701 IPR001965
domain Tudor domain 11 - 71 IPR002999-1
domain Tudor domain 85 - 141 IPR002999-2
domain Zinc finger C2H2-type 455 - 485 IPR013087
conserved_site Zinc finger, PHD-type, conserved site 658 - 700 IPR019786
domain PHD finger protein 20, AT hook 176 - 280 IPR022255
domain DNA repair protein Crb2, Tudor domain 90 - 136 IPR041297

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

6 GO annotations of cellular component

Name Definition
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
histone acetyltransferase complex A protein complex that possesses histone acetyltransferase activity.
MLL1 complex A protein complex that can methylate lysine-4 of histone H3. MLL1/MLL is the catalytic methyltransferase subunit, and the complex also contains the core components ASH2L, HCFC1/HCF1 WDR5 and RBBP5.
NSL complex A histone acetyltransferase complex that catalyzes the acetylation of a histone H4 lysine residues at several positions. In human, it contains the catalytic subunit MOF, NSL1/KIAA1267, NSL2/KANSL2, NSL3/KANSL3, MCRS1, PHF20, OGT1, WDR5 and HCF1.
nuclear membrane Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space.
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.

2 GO annotations of molecular function

Name Definition
DNA binding Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).
metal ion binding Binding to a metal ion.

9 GO annotations of biological process

Name Definition
chromatin organization The assembly or remodeling of chromatin composed of DNA complexed with histones, other associated proteins, and sometimes RNA.
histone acetylation The modification of a histone by the addition of an acetyl group.
histone H4-K16 acetylation The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 16 of the histone.
histone H4-K5 acetylation The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 5 of the histone.
histone H4-K8 acetylation The modification of histone H4 by the addition of an acetyl group to a lysine residue at position 8 of the histone.
positive regulation of DNA-templated transcription Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.
positive regulation of histone H3-K4 methylation Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3.
regulation of dosage compensation by inactivation of X chromosome Any process that modulates the frequency, rate or extent of dosage compensation, by inactivation of X chromosome.
regulation of transcription by RNA polymerase II Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II.

2 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
A2VE56 PHF20L1 PHD finger protein 20-like protein 1 Bos taurus (Bovine) PR
Q9BVI0 PHF20 PHD finger protein 20 Homo sapiens (Human) PR
10 20 30 40 50 60
MTKHPPNRRG ISFEVGAQLE ARDRLKNWYP AHIEDIDYEE GRVLIHFKRW NHRYDEWFCW
70 80 90 100 110 120
DSPYLRPLEK IQLRKEGLHD EDGSSEFQIN QQVLACWSDC RFYPARVTAV NKDGTYTVKF
130 140 150 160 170 180
YDGVVQTVKH IHVKAFSKDQ NIVGNARPKE TDHKSLSSSP EKREKFKEQR KVTVNVKKDK
190 200 210 220 230 240
VEKALKTEKR PKQPDKEGKL ICSEKGKVSE KSLPKNEKED KENISENERE YSGDAQVEKK
250 260 270 280 290 300
PEKDLVKNPQ ENLKEPKRKR GRPPSITPTA VDSNSQTLQP ITLELRRRKI SKRSDTPLKR
310 320 330 340 350 360
PRLDKNSPQE QSKKRSENSD KDLSRRRSSR LSTNGTREIL DPDSIVPDLV HTVDTNPLPD
370 380 390 400 410 420
KSPSAKDSAE GQLKSPLEAG QVSSALTCHP IGDGLGAADL ELNCKSMGEN TMKTEPVSPL
430 440 450 460 470 480
AEVQEVSTVE VPNTLKKVDD SVTLNVPAVD LDHKFRCKVL DCLKFFRKAK LLHYHMKYFH
490 500 510 520 530 540
GMEKSPEPEE GPGKTHVQTR GSAVPDKTSQ ESLTRKRVSA SSPTAKEKEK TKEKKFKELV
550 560 570 580 590 600
RVKPKKKKKK KKKTKPECPC SEDISDTSQE PSPPKTFAVT RCGSSHKPGV HMSPQLHGSD
610 620 630 640 650 660
NGNHKGKLKT CEEDNLSESS SESFLWSDEE YGQDVDVTTN PDEELEGDDR YDFEVVRCIC
670 680 690 700 710 720
EVQEENDFMI QCEECQCWQH GVCMGLLEEN VPEKYTCYVC QDPPGQRPGF KYWYDKEWLS
730 740 750 760 770 780
RGHMHGLAFL DQNYSHQNAR KIVATHQLLG DVQRVIQVLH GLQLKMSILQ SREHPDLQLW
790 800 810 820 830 840
CQPWKQHSGE GRAHPRHIHI TDARSEESPS YRTLNGAVEK PSPLPRSVEE SYITSEHCYQ
850 860 870 880 890 900
KPRAYYPAVE QRLVVETRGS ALDAAVSPLC ENGDDSLSPR LGWPIDQDRS RGDIDPKPSS
910 920 930 940 950 960
PKVREYISKN VLPEETPARK LLDRGGEGLV SSQHQWQFNL LTHVESLQDE VTHRMDSIEK
970 980 990 1000
ELDVLESWLD YTGELEPPEP LARLPQLKHC IKQLLTDLGK VQQIALCCST